Ketanserin, a Novel 5-Hydroxytryptamine Antagonist: Monotherapy in Essential Hypertension.

British Journal of Clinical Pharmacology- United Kingdom

doi 10.1111/j.1365-2125.1983.tb04974.x

Full Text

Abstract

Available in

Categories

Date

August 1, 1983

Authors

Publisher

Wiley

Related search

Treatment of Hypertension With Ketanserin, a New Selective 5-Ht2 Receptor Antagonist.

English

Ketanserin in Essential Hypertension: A Double-Blind, Placebo-Controlled Study.

Postgraduate Medical Journal

English

Adequacy of Olmesartan Monotherapy Versus Cotherapy in Patients With Essential Hypertension

International Journal of Research in Pharmaceutical Sciences

English

5-Hydroxytryptamine

Postgraduate Medical Journal

English

The Effect of a 5-Ht Antagonist, Ketanserin, on Blood Pressure, the Renin-Angiotensin System and Sympathoadrenal Function in Normal Man.

British Journal of Clinical Pharmacology

English

Treatment Patterns Among Patients Prescribed Pde-5 Inhibitor Monotherapy for Pulmonary Hypertension

Value in Health

Occupational Health

English

Peroxisome Proliferator-Activated Receptor- Ameliorates Pulmonary Arterial Hypertension by Inhibiting 5-Hydroxytryptamine 2B Receptor

Internal Medicine

English

Robalzotan (NAD-299), a Novel Selective 5-Ht 1A Receptor Antagonist

CNS Drug Reviews

English

Cardiac Effects of Ketanserin, a Serotonin Antagonist. Electrophysiological Examinations as a Part of Toxicity Studies.

Journal of Toxicological Sciences

English